A newspaper report revealed south china post ugn An experimental coronavirus vaccine based on technology has been approved mRNA Chinese for late-stage clinical trials in Mexico after months of delay, as well as in Indonesia.
According to the report, the vaccine ARCoV It was approved for Phase 3 trials by drug regulators in Mexico on August 19 and in Indonesia on August 27.
Corona new vaccine
The announcement came days after the vaccine manufacturer obtained approval from the Nepalese government to conduct Phase III trials on 3,000 people there, according to a report by the official Chinese news agency Xinhua, citing a Nepalese health official..
Trials are also being conducted in China in Yunnan Province and Guangxi Zhuang Province, although the coronavirus is no longer circulating in the country..
Phase 3 trials will test the efficacy, safety, and immune response triggered by the vaccine in people aged 18 and over, early registration records appear with online database ClinicalTrials.gov About 28,000 people who will participate in trials worldwide, with at least 25% of them over the age of 60, will be randomly assigned to study and control groups and given two doses of the experimental vaccine or placebo over a 28-day period..
Works ARCoV by RNA delivery (RNA), or RNA (ribonucleic acid), which directs human cells to produce proteins, which train the immune system to respond in the presence of a real virus.
China relied mostly on inactivated vaccines in its mass vaccination campaign against Corona, but studies have shown that they are less effective than vaccines mRNA The authorities encouraged drug makers to develop new vaccines using other technologies.
Many Chinese drug makers are also experimenting with other technologies, including mRNA and protein-based and adenovirus-directed vaccines.